| scholarly article | Q13442814 |
| P50 | author | Yurong Lai | Q51696405 |
| P2093 | author name string | Adrian S Ray | |
| Laurent Salphati | |||
| Jashvant D Unadkat | |||
| Edward J Kelly | |||
| Cornelis E C A Hop | |||
| Raymond Evers | |||
| W Griffith Humphreys | |||
| Anita Mathias | |||
| Guangqing Xiao | |||
| Mingxiang Liao | |||
| Xiaoyan Chu | |||
| Bhagwat Prasad | |||
| Sarah Billington | |||
| Caroline A Lee | |||
| Christopher Rowbottom | |||
| P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
| Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma | Q22305316 | ||
| Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics | Q26851693 | ||
| Sofosbuvir/velpatasvir: A promising combination | Q27468954 | ||
| Hepatocellular carcinoma: a review | Q28069290 | ||
| DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma | Q28383720 | ||
| Liver fibrosis | Q29547449 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Epidemiology of viral hepatitis and hepatocellular carcinoma | Q29617918 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. | Q34206748 | ||
| New use for an old drug: inhibiting ABCG2 with sorafenib | Q34275508 | ||
| The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma | Q34291784 | ||
| Estimating progression to cirrhosis in chronic hepatitis C virus infection. | Q34389608 | ||
| An analysis of 412 cases of hepatocellular carcinoma at a Western center | Q34503813 | ||
| The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? | Q35593034 | ||
| Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations | Q35905037 | ||
| Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry | Q35913104 | ||
| Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide | Q36698681 | ||
| Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites | Q36852518 | ||
| Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 | Q36998199 | ||
| Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease | Q37112127 | ||
| Hepatitis C virus infection and hepatocellular carcinoma | Q37215796 | ||
| Surveillance and epidemiology of hepatitis B and C in Europe - a review. | Q37257831 | ||
| Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex | Q37422685 | ||
| Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation | Q37760651 | ||
| Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics | Q38829596 | ||
| Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking | Q38933714 | ||
| Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1. | Q39255340 | ||
| Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response | Q39449507 | ||
| Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics | Q39683666 | ||
| Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. | Q39712719 | ||
| Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation | Q39747662 | ||
| Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta | Q40054391 | ||
| Classification of chronic hepatitis: diagnosis, grading and staging | Q40755087 | ||
| Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics | Q41585282 | ||
| Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver | Q42611215 | ||
| Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model | Q42682232 | ||
| Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. | Q42997033 | ||
| In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein | Q43088275 | ||
| Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci | Q43687623 | ||
| Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. | Q43802618 | ||
| Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States | Q45731239 | ||
| OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation | Q46303391 | ||
| Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide | Q46317002 | ||
| Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in | Q46565181 | ||
| Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma | Q47912725 | ||
| Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development | Q50062283 | ||
| The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. | Q50177933 | ||
| Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. | Q50876461 | ||
| Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system | Q53026443 | ||
| Selective inhibition of human solute carrier transporters by multikinase inhibitors. | Q54326668 | ||
| Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. | Q54400196 | ||
| Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. | Q54418028 | ||
| Hepatobiliary transporter expression in human hepatocellular carcinoma. | Q54674953 | ||
| High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. | Q54762269 | ||
| Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid | Q57154102 | ||
| Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype | Q57684358 | ||
| Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging | Q72246149 | ||
| Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths | Q74604755 | ||
| Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) | Q80128982 | ||
| Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria | Q80548014 | ||
| P4510 | describes a project that uses | liquid chromatography–mass spectrometry | Q873864 |
| liquid chromatography-tandem mass spectrometry | Q117788892 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 189-196 | |
| P577 | publication date | 2017-11-14 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics | |
| P478 | volume | 46 |
| Q88657543 | Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium |
| Q91179158 | Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics |
| Q91165087 | Protein abundance of hepatic drug transporters in patients with different forms of liver damage |
| Q92895937 | STAT3 signaling pathway plays importantly genetic and functional roles in HCV infection |
| Q92217096 | Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1 |
Search more.